CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

CVS Caremark estimates between 25 to 30 million people use ... Though the two drugs are both approved for weight loss, a study published in May funded by Eli Lilly found that patients on Zepbound were ...

A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound from its preferred list, making rival ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...